We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Curcumin Flushes Out Plaques in Alzheimer's Disease

By Biotechdaily staff writers
Posted on 20 Oct 2006
Researchers have discovered that curcumin--a chemical found in curry and turmeric--may help the immune system clear the brain of amyloid beta, which form the plaques found in Alzheimer's disease (AD) patients.

Published in the October 9, 2006, issue of the Journal of Alzheimer's Disease, these early findings may lead to a new approach in treating AD by enhancing the natural function of the immune system using curcumin, known for its anti-inflammatory and anti-oxidant properties.

Using blood samples from six AD patients and three healthy control patients, the researchers isolated cells called macrophages, which are the immune system's cleaning team that travel through the brain and body, gulping up waste products, including amyloid beta.

The team of researchers, from the University of California, Los Angeles (UCLA; USA)/Veterans Administration (VA), treated the macrophages with a drug derived from curcumin for 24 hours in a cell culture and then introduced amyloid beta. More...
Treated macrophages from three out of six AD patients showed improved uptake or ingestion of the waste product compared to the patients' macrophages not treated with curcumin. Macrophages from the healthy controls, which were already effectively clearing amyloid beta, showed no change when curcumin was added.

"Curcumin improved ingestion of amyloid beta by immune cells in 50% of patients with Alzheimer's disease. These initial findings demonstrate that curcumin may help boost the immune system of specific Alzheimer's disease patients,” said Dr. Milan Fiala, study author and a researcher with the David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System. "We are hopeful that these positive results in a test tube may translate to clinical use, but more studies need to be done before curcumin can be recommended.” The patients ranged in age from 65 to 84.

Dr. Fiala noted that the patients whose immune cells responded were younger and had higher scores on a Mini-Mental State Examination, suggesting that curcumin may help those with less advanced dementia. Some of the patients may have already had additional curcumin in their systems due to participation in another UCLA study, which may have impacted findings.

"Our next step will be to identify the factors that helped these immune cells respond,” said Dr. Laura Zhang, a study author and a UCLA/VA research assistant in Dr. Fiala's lab.

Dr. Fiala noted that the method researchers used to assess the immune cell response of macrophages may provide an innovative way of evaluating the effectiveness of drugs in clearing amyloid beta from the brain and may help to customize Alzheimer's disease treatment.

According to Dr. Fiala, macrophages are the defense forces of the innate immune system--the part of the immune system that is present at birth. Curcumin may support the body's natural immune fighting function in directly helping macrophages clean away amyloid-beta. The treatment of macrophages with curcumin is fundamentally different from some of the vaccine approaches currently being investigated.



Related Links:
University of California, Los Angeles

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.